Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern

QR Code

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern

SARS-CoV-2 has caused the COVID-19 pandemic, with over 673 million infections and 6.85 million deaths globally. Novel mRNA and viral-vectored vaccines were developed and licensed for global immunizations under emergency approval. They have demonstrated good safety and high protective efficacy agains...

Full description

Bibliographic Details
Main Authors:	Abdul Aziz, Al-Fattah Yahaya , Kanwal, Khalid , Lim, Hui Xuan , Poh, Chit Laa
Format:	Article
Language:	English
Published:	MDPI 2023
Subjects:	RA Public aspects of medicine
Online Access:	http://eprints.sunway.edu.my/2161/ http://eprints.sunway.edu.my/2161/1/viruses-15-00624-v2.pdf

Similar Items

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
by: Lim, Hui Xuan *, et al.
Published: (2021)

Development of multi-epitope peptide-based vaccines against SARS-CoV-2
by: Lim, Hui Xuan *, et al.
Published: (2020)

The SARS-CoV-2 variants and their impacts
by: Akmal Shukri, Amir Muhaimin, et al.
Published: (2022)

Construction of multi-epitopes vaccine candidate against SARS-CoV-2 D614G variant
by: Siti Asmaa Mat Jusoh,, et al.
Published: (2022)

Identification of B-cell epitopes for eliciting neutralizing antibodies against the SARS-CoV-2 spike protein through bioinformatics and monoclonal antibody targeting
by: Lim, Hui Xuan *, et al.
Published: (2022)

In silico selection of aptamers against SARS-CoV-2
by: Akmal Shukri, Amir Muhaimin, et al.
Published: (2024)

On-site sequencing of Sars-Cov-2 genomes identify two variant of concern clusters in Pahang, Malaysia
by: Ummu Afeera, Zainulabid, et al.
Published: (2023)

Concerns regarding SARS-CoV-2 JN.1 mutations should be raised
by: Roney, Miah, et al.
Published: (2024)

Genomic epidemiology of SARS-CoV-2 in Malaysia
by: Chew, Sian Hui
Published: (2025)

Pathophysiology, histopathology and therapeutic of SARS-CoV-2
by: Noman, Efaq, et al.
Published: (2020)

Lateral flow immunoassays for SARS-CoV-2
by: Ang, Geik Yong, et al.
Published: (2022)

NK cells: A double edge sword against SARS-CoV-2
by: Masselli, E., et al.
Published: (2020)

Insights into innate and adaptive immune responses in vaccine development against EV-A71
by: Lim, Hui Xuan *, et al.
Published: (2019)

Humoral response to SARS-CoV-2 vaccines among healthcare workers in a tertiary hospital in Malaysia
by: Mohd Amin, Amrina, et al.
Published: (2022)

Development of antivirals and vaccines against enterovirus 71 (EV-A71)
by: Poh, Chit Laa *
Published: (2018)

The cell mediated and humoral response to SARS-CoV-2 infection
by: Burns, Eleanor
Published: (2022)

Thermophoretic collection of virus-laden (SARS-CoV-2) aerosols
by: Zhang, Xiangzhi, et al.
Published: (2021)

SARS-CoV-2 screening must go beyond sick
by: Abdullah, Syahril
Published: (2020)

Defining the clinicoradiologic syndrome of SARS-CoV-2 acute necrotizing encephalopathy
by: Lee, Vanessa W., et al.
Published: (2024)

SARS-CoV-2: from origin to treatment and control management strategies
by: Hezam, Kamal, et al.
Published: (2020)

Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
by: Masomian, Malihe *, et al.
Published: (2020)

Development of novel vaccines against Enterovirus-71
by: Yee, Isabel Pin Tsin *, et al.
Published: (2015)

Recent advances in delivery of veterinary DNA vaccines against avian pathogens
by: Jazayeri, S. D. *, et al.
Published: (2019)

Risk Perceptions of SARS-CoV-2 in the UK: A City-wise Analysis
by: Raza, Naba
Published: (2022)

SARS-CoV-2 infection and human semen: possible modes of contamination and transmission
by: Bhattacharya, Koushik, et al.
Published: (2021)

Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: from alpha to Omicron
by: Choo, Yee Yu, et al.
Published: (2022)

Coronavirus (SARS-COV-2) in early stages of the pandemic; overview
by: Al-Gheethi, Adel, et al.
Published: (2020)

Nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases
by: Jazayeri, S. D. *, et al.
Published: (2021)

Apa yang berlaku pada tubuh apabila berlaku jangkitan SARS-CoV-2 ?
by: Mohd Nasir, Mohd Hamzah
Published: (2020)

Isolation and characterisation of bovine ultralong antibodies to SARS-CoV-2 using phage display
by: Park, Emily
Published: (2024)

Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach
by: Mok, Pooi Ling, et al.
Published: (2021)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
by: T. Selvavinayagam, Sivaprakasam, et al.
Published: (2022)

A Fog Computing-based System to Identify SARS - CoV -2 Using Deep Learning
by: Welhenge, Anuradhi
Published: (2021)

Identification of SARS-CoV-2 inhibitors from alkaloids using molecular modeling and in silico approaches
by: Roni, Md Abul Hasan, et al.
Published: (2023)

Development of novel miRNA-based vaccines and antivirals against Enterovirus 71
by: Yee, Isabel Pin Tsin *, et al.
Published: (2016)

Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
by: Chua, Jia Xin, et al.
Published: (2022)

Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1
by: Chan, Lee-Chin, et al.
Published: (2023)

Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease
by: Mohd Ishtiaq Anasir, *, et al.
Published: (2019)

Nutrients, herbal bioactive derivatives and commensal microbiota as tools to lower the risk of SARS-CoV-2 infection
by: Romani, Arianna, et al.
Published: (2023)

Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic
by: Lins, Brittney
Published: (2021)